Clinical Trial Update: Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease [Phase 3]

View source ↗

Summary

This entry reports the completion and posted results of a Phase 3 trial comparing Fluticasone Furoate/Vilanterol inhalation powder (FF/VI) to Tiotropium inhalat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BREO ELLIPTA (fluticasone furoate and vilanterol trifenatate)
• Spiriva (tiotropium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2013-11-01